Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen species

Anti-Cancer Drugs

Volumn 17, Issue 6, 2006, Pages 609-619

  Haupt, Sue ^a   Kleinstern, Jackie ^b   Haupt, Ygal ^c   Rubinstein, Abraham ^b  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c HEBREW UNIVERSITY   (Israel)

Author keywords

c Abl; Celecoxib; Colorectal cancer; Hdm2; p53; Reactive oxygen species; Xanthine oxidase

Indexed keywords

ABELSON KINASE; ANTIOXIDANT; CELECOXIB; CYCLOOXYGENASE 2; PROTEIN MDM2; PROTEIN P53; REACTIVE OXYGEN METABOLITE; SUPEROXIDE; XANTHINE OXIDASE;

ANIMAL CELL; ARTICLE; CELL DEATH; CELL GROWTH; CELL LINE; CELL PROTECTION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG MECHANISM; EMBRYO; ENZYME SYNTHESIS; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE;

ADENOCARCINOMA; ANIMALS; ANTIOXIDANTS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL PROLIFERATION; CELLS, CULTURED; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; EMBRYO; EMBRYO, MAMMALIAN; FIBROBLASTS; HUMANS; MICE; MICE, KNOCKOUT; PROTO-ONCOGENE PROTEINS C-ABL; PROTO-ONCOGENE PROTEINS C-MDM2; PYRAZOLES; REACTIVE OXYGEN SPECIES; SULFONAMIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33747626285     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.cad.0000215055.40072.42     Document Type: Article

References (58)

1. 2 is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun 2003; 306:887-897.
2. Corcoran CA, He Q, Huang Y, Sheikh MS. Cyclooxygenase-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis. Oncogene 2005; 24:1634-1640.
3. Moos PJ, Edes K, Fitzpatrick FA. Inactivation of wild-type p53 tumor suppressor by electrophilic prostaglandins. Proc Natl Acad Sci U S A 2000; 97:9215-9220.
4. Swamy MV, Herzog CR, Rao CV. Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res 2003; 63:5239-5242.
5. Smith CJ, Zhang Y, Koboldt CM, Muhammad J, Zweifel BS, Shaffer A, et al. Pharmacological analysis of cyclooxygenase-1 in inflammation. Proc Natl Acad Sci U S A 1998; 95:13313-13318.
6. Schonthal AH. Correspondence re: M. V. Swamy et al., Inhibition of COX-2 in colon cancer cell lines by celecoxib increases the nuclear localization of active p53. Cancer Res 2003;63:5239-5242.
7. Cancer Res 2004; 64:2937; author reply 2938.
8. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004; 15:177-182.
9. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 2000; 275:11397-11403.
10. Arico S, Pattingre S, Bauvy C, Gane P, Barbat A, Codogno P, Ogier-Denis E. Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line. J Biol Chem 2002; 277:27613-27621.
11. Zhang Z, Lai GH, Sirica AE. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 2004; 39:1028-1037.
12. Kulp SK, Yang YT, Hung CC, Chen KF, Lai JP, Tseng PH, et al. 3-Phosphoinositide-dependent protein kinase-1/Akt signaling represents a major cyclooxygenase-2-independent target for celecoxib in prostate cancer cells. Cancer Res 2004; 64:1444-1451.
13. McMasters KM, Montes de Oca Luna R, Pena JR, Lozano G. Mdm2 deletion does not alter growth characteristics of p53-deficient embryo fibroblasts. Oncogene 1996; 13:1731-1736.
14. Tybulewicz VL, Crawford CE, Jackson PK, Bronson RT, Mulligan RC. Neonatal lethality and lymphopenia in mice with a homozygous disruption of the c-abl proto-oncogene. Cell 1991; 65:1153-1163.
15. Mossman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:5-63.
16. Okado-Matsumoto A, Fridovich I. Assay of superoxide dismutase: cautions relevant to the use of cytochrome c, a sulfonated tetrazolium, and cyanide. Anal Biochem 2001; 298:337-342.
17. Tan AS, Berridge MV. Superoxide produced by activated neutrophils efficiently reduces the tetrazolium salt, WST-1 to produce a soluble formazan: a simple colorimetric assay for measuring respiratory burst activation and for screening anti-inflammatory agents. J Immunol Methods 2000; 238:59-68.
18. Wenzel U, Nickel A, Kuntz S, Daniel H. Ascorbic acid suppresses drug-induced apoptosis in human colon cancer cells by scavenging mitochondrial superoxide anions. Carcinogenesis 2004; 25:703-712.
19. Rosati E, Sabatini R, Ayroldi E, Tabilio A, Bartoli A, Bruscoli S, et al. Apoptosis of human primary B lymphocytes is inhibited by N-acetyl-L-cysteine. J Leuk Biol 2004; 76:152-161.
20. Hsi LC, Baek SJ, Eling TE. Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells. Exp Cell Res 2000; 256:563-570.
21. Li M, Wu X, Xu XC. Induction of apoptosis in colon cancer cells by cyclooxygenase-2 inhibitor NS398 through a cytochrome c-dependent pathway. Clin Cancer Res 2001; 7:1010-1016.
22. Bernas T, Dobrucki J. Mitochondrial and nonmitochondrial reduction of MTT: interaction of MTT with TMRE, JC-1, and NAO mitochondrial fluorescent probes. Cytometry 2002; 47:236-242.
23. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63.
24. Madesh M, Balasubramanian KA. Microtiter plate assay for superoxide dismutase using MTT reduction by superoxide. Indian J Biochem Biophys 1998; 35:184-188.
25. Ukeda H, Shimamura T, Tsubouchi M, Harada Y, Nakai Y, Sawamura M. Spectrophotometric assay of superoxide anion formed in Maillard reaction based on highly water-soluble tetrazolium salt. Anal Sci 2002; 18:1151-1154.
26. Pruett SB, Loftis AY. Characteristics of MTT as an indicator of viability and respiratory burst activity of human neutrophils. Int Arch Allergy Appl Immunol 1990; 92:189-192.
27. Ishiyama M, Shiga M, Sasamoto K, Mizoguchi M, He P-G. A new sulfonated tetrazolium salt that produces a highly water-soluble formazan dye. Chem Pharm Bull 1993; 41:1118-1122.
28. Cervi D, Truong AH, Lee JS, Sukhai N, Li YJ, Koki A, Ben-David Y. Phosphorylation status of c-Kit and Epo receptors, and the presence of wild-type p53 confer in vitro resistance of murine erythroleukemic cells to celecoxib. Oncogene 2004; 23:2305-2314.
29. Bernas T, Dobrucki JW. The role of plasma membrane in bioreduction of two tetrazolium salts, MTT, and CTC. Arch Biochem Biophys 2000; 380:108-116.
30. Chang-Hui L, Yen-Ju H, Yin-Chou L. Celecoxib simulates respiratory burst through pertussis toxin-sensitive G-protein, a possible signal for beta2-integrin expression on human neutrophils. Eur J Pharmacol 2004; 484:29-39.
31. Takahashi T, Ogawa Y, Kobayashi T, Sonobe H, Seguchi H, Tani T, Yoshida S. The role of selective COX-2 inhibitors in reactive oxygen species formation in osteosarcoma cells after X-ray irradiation. Int J Mol Med 2004; 13:661-664.
32. Lee E, Choi MK, Youk HJ, Kim CH, Han IO, Yoo BC, et al. 5-(4-Chlorophenyl)-1-(4-methoxyphenyl)-3-trifluoromethylpyrazole acts in a reactive oxygen species-dependent manner to suppress human lung cancer growth. J Cancer Res Clin Oncol 2006; 132:223-233.
33. Levitt RJ, Buckley J, Blouin MJ, Schaub B, Triche TJ, Pollak M. Growth inhibition of breast epithelial cells by celecoxib is associated with upregulation of insulin-like growth factor binding protein-3 expression. Biochem Biophys Res Commun 2004; 316:421-428.
34. Hou CC, Hung SL, Kao SH, Chen TH, Lee HM. Celecoxib induces hemeoxygenase expression in glomerular mesangial cells. Ann N Y Acad Sci 2005; 1042:235-245.
35. Applegate LA, Luscher P, Tyrrell RM. Induction of heme oxygenase: a general response to oxidant stress in cultured mammalian cells. Cancer Res 1991; 51:974-978.
36. Fang J, Sawa T, Akaike T, Greish K, Maeda H. Enhancement of chemotherapeutic response of tumor cells by a heme oxygenase inhibitor, pegylated zinc protoporphyrin. Int J Cancer 2004; 109:1-8.
37. Haider A, Olszanecki R, Gryglewski R, Schwartzman ML, Lianos E, Kappas A, et al. Regulation of cyclooxygenase by the heme-heme oxygenase system in microvessel endothelial cells. J Pharmacol Exp Ther 2002; 300:188-194.
38. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002; 82:47-95.
39. Pritsos CA. Cellular distribution, metabolism and regulation of the xanthine oxidoreductase enzyme system. Chem Biol Interact 2000; 129:195-208.
40. Tsang WP, Chau SP, Kong SK, Fung KP, Kwok TT. Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis. Life Sci 2003; 73:2047-2058.
41. Sun X, Majumder P, Shioya H, Wu F, Kumar S, Weichselbaum R, et al. Activation of the cytoplasmic c-Abl tyrosine kinase by reactive oxygen species. J Biol Chem 2000; 275:17237-17240.
42. Bensaad K, Vousden KH. Savior and slayer: the two faces of p53. Nat Med 2005; 11:1278-1279.
43. Rizzuto R, Pinton P, Ferrari D, Chami M, Szabadkai G, Magalhaes PJ, et al. Calcium and apoptosis: facts and hypotheses. Oncogene 2003; 22:8619-8627.
44. 2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. Biochem J 2002; 366:831-837.
45. 2+ movement and cell proliferation in human osteoblasts. Biochem Pharmacol 2004; 67:1123-1130.
46. De Miguel MP, Cheng L, Holland EC, Federspiel MJ, Donovan PJ. Dissection of the c-kit signaling pathway in mouse primordial germ cells by retroviral-mediated gene transfer. Proc Natl Acad Sci U S A 2002; 99:10458-10463.
47. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001; 15:2742-2744.
48. Kundu N, Smyth MJ, Samsel L, Fulton AM. Cyclooxygenase inhibitors block cell growth, increase ceramide and inhibit cell cycle. Breast Cancer Res Treat 2002; 76:57-64.
49. 2 arrest after DNA damage. Science 1998; 282:1497-501.
50. Kaeser MD, Pebernard S, Iggo RD. Regulation of p53 stability and function in HCT116 colon cancer cells. J Biol Chem 2004; 279:7598-7605.
51. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, et al. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99:2254-2259.
52. Alarcon R, Koumenis C, Geyer RK, Maki CG, Giaccia AJ. Hypoxia induces p53 accumulation through MDM2 down-regulation and inhibition of E6-mediated degradation. Cancer Res 1999; 59:6046-6051.
53. Abdelrahim M, Safe SH. Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. Mol Pharmacol 2005; 68:317-329.
54. Schumacher U, Adam E, Feldhaus S, Katoh M, Lane DP. Cell differentiation and chemotherapy influence p53 and Mdm2 immunoreactivity in human HT29 colon cancer cells grown in scid mice. Cancer Lett 2001; 166:215-221.
55. Zhou R, Frum R, Deb S, Deb SP. The growth arrest function of the human oncoprotein mouse double minute-2 is disabled by downstream mutation in cancer cells. Cancer Res 2005; 65:1839-1848.
56. Half E, Tang XM, Gwyn K, Sahin A, Wathen K, Sinicrope FA. Cyclooxygenase-2 expression in human breast cancers and adjacent ductal carcinoma in situ. Cancer Res 2002; 62:1676-1681.
57. Wang H, Yu D, Agrawal S, Zhang R. Experimental therapy of human prostate cancer by inhibiting MDM2 expression with novel mixed-backbone antisense oligonucleotides: in vitro and in vivo activities and mechanisms. Prostate 2003; 54:194-205.
58. Patel MI, Subbaramaiah K, Du B, Chang M, Yang P, Newman RA, et al. Celecoxib inhibits prostate cancer growth: evidence of a cyclooxygenase-2- independent mechanism. Clin Cancer Res 2005; 11:1999-2007.